Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synthetic lethal targeting of TET2-mutant hematopoietic stem and progenitor cells (HSPCs) with TOP1-targeted drugs and PARP1 inhibitors.

Leukemia - 1 Nov 2020

Jing Chang-Bin, Fu Cong, Prutsch Nicole, Wang Meng, He Shuning, Look A Thomas

Abstract excerpt

Inactivating mutations in TET2 serve as an initiating genetic lesion in the transformation of hematopoietic stem and progenitor cells (HSPCs). Thus, effective therapy for this subset of patients would ideally include drugs that are selectively lethal in TET2-mutant HSPCs, at dosages that spare normal HSPCs. In this study, we tested 129 FDA-approved anticancer drugs in a tet2-deficient zebrafish model and showed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animals, Genetically Modified
Share to Dioxygenases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Breaks, Double-Stranded

Share to DNA Topoisomerases, Type I

Share to Hematopoietic Stem Cells

Share to Poly (ADP-Ribose) Polymerase-1

Share to Synthetic Lethal Mutations

Share to Topoisomerase I Inhibitors

Source

Identifiers

PMID: 32572188
DOI: 10.1038/s41375-020-0927-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synthetic lethal targeting of TET2-mutant hematopoietic stem and progenitor cells (HSPCs) with TOP1-targeted drugs and PARP1 inhibitors.PMID 32572188Read ↗

Synthetic lethal targeting of <i>TET2</i> -mutant hematopoietic stem and progenitor cells by XPO1 inhibitorsSemantic proximity Read ↗

A zebrafish model of myelodysplastic syndrome produced through tet2 genomic editing.Semantic proximity Read ↗

TDP2–Dependent Non-Homologous End-Joining Protects against Topoisomerase II–Induced DNA Breaks and Genome Instability in Cells and In VivoSemantic proximity Read ↗

TET2 Deficiency Increases the Competitive Advantage of Hematopoietic Stem Cells through Upregulation of Thrombopoietin Receptor SignalingSemantic proximity Read ↗

TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors.Semantic proximity Read ↗

Topoisomerase II poisons inhibit vertebrate DNA replication through distinct mechanismsSemantic proximity Read ↗

A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenase–Deficient Cells in Myeloid NeoplasmsSemantic proximity Read ↗

Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage.Semantic proximity Read ↗

Analysis of Gene Expression Changes upon Topobexin Treatment and TOP2B-knockout in hiPSC derived cardiomyocytesSemantic proximity Read ↗

Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugsSemantic proximity Read ↗

Biallelic TET2 mutations confer sensitivity to 5'-azacitidine in acute myeloid leukemia.Semantic proximity Read ↗

Etoposide-induced DNA damage is increased in p53 mutants: identification of ATR and other genes that influence effects of p53 mutations on Top2-induced cytotoxicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.